◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Mankind Pharma Limited (MANKIND) Revenue 2023–2026

Name: Mankind Pharma Limited (MANKIND) revenue history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Mankind Pharma Limited annual revenue for fiscal 2026 was ₹142.8 billion, an increase of 17.0% from ₹122.1 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

MANKIND Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹142.8B	₹122.1B	₹102.6B	₹87.5B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MANKIND Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹40.3B	₹34.4B	₹35.7B	₹35.7B	₹30.8B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

LAURUSLABS Revenue — Laurus Labs Limited
AUROPHARMA Revenue — Aurobindo Pharma Limited
DRREDDY Revenue — Dr. Reddy's Laboratories Limited
LUPIN Revenue — Lupin Limited
4506 Revenue — Sumitomo Pharma Co., Ltd.
GLENMARK Revenue — Glenmark Pharmaceuticals Limited

More MANKIND metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All MANKIND financial statements → Interactive MANKIND charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.